Chugai Obtains Approval for FoundationOne Liquid CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for Novartis MET Inhibitor, Capmatinib.
In: ENP Newswire, 2023-05-29
Zeitungsartikel
Zugriff:
Titel: |
Chugai Obtains Approval for FoundationOne Liquid CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for Novartis MET Inhibitor, Capmatinib.
|
---|---|
Link: | |
Zeitschrift: | ENP Newswire, 2023-05-29 |
Veröffentlichung: | 2023 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|